Experimental gene therapy for prostate cancer Treatment of mouse prostate cancer with adenovirus mediated interleukin-12 gene transduction alone and in combination with herpes simplex virus thymidine kinase gene transduction and ganciclovir therapy. Journal of Urology 159(5 SUPPL ): 1, 1998
Effect of interleukin-2 gene therapy on prostate specific antigen in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer. Journal of Urology 161(4 SUPPL ): 337, 1999
Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Human Gene Therapy 7(4): 515-523, 1996
Targeting prostate cancer gene therapy Comparative analysis of the activity of prostate specific promoters and enhancer sequences in prostate cancer cells. Journal of Urology 165(5 Suppl.): 45, 2001
Prostate cancer gene therapy HSV-tk gene transduction followed by ganciclovir in the mouse prostate reconstitution model system. Journal of Urology 153(4 SUPPL ): 307A, 1995
The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urologic Oncology 33(5): 202.E19-28, 2016
Gene therapy for human prostate cancer: Translational research in the hormone refractory Dunning prostate cancer model. Cancer 75(7 SUPPL.): 2013-2020, 1995
New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62(5 Suppl 1): 34-43, 2003
The retroviral vector MFG allows high efficiency transduction of human prostate cancer cells Implications for gene therapy of prostate cancer. Journal of Cellular Biochemistry Suppl. 0(17 PART D): 120, 1993
Molecular characterization of heterogeneity in immune evasion by human prostate cancer cells Implications for prostate cancer gene therapy. Journal of Urology 151(5 SUPPL ): 254A, 1994
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. British Journal of Cancer 81(4): 672-676, 1999
Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Research 59(2): 382-390, 1999
Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth. Plos One 11(4): E0153350, 2016
Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Research 34(12): 7159-7165, 2015
Construction of a prostate specific antigen promoter-driven gene transfer vector A novel strategy for target specific gene therapy in prostate cancer. Journal of Urology 151(5 SUPPL ): 491A, 1994